Company · insightec-e0866930
InSightec
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. InSightec. Companies, record insightec-e0866930. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/insightec-e0866930
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- InSightec
- Trials
- 95
- As lead sponsor
- 84
- As collaborator
- 11
- Recruiting
- 10
- Active, recruiting or not
- 26
- Completed
- 52
- Stopped early, withdrawn or suspended
- 14
- Posted results
- 16
- Trials by phase
- Phase 1 8, Phase 2 9, Phase 3 4, Phase 4 1
- Drugs its trials test
- 10
- Comparisons calculated in its trials
- 6
- First trial registered
- 2003-01-27
- Last update
- 2026-11-06
Source ClinicalTrials.gov
Pipeline10
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| PEMBROLIZUMAB | Phase 3 | 2 | 1 | 1 | PDCD1 | Programmed cell death protein 1 inhibitor | https://conductscience.org/library/drugs/CHEMBL3137343 | Open Targets |
| ATEZOLIZUMAB | Phase 3 | 1 | 1 | 1 | CD274 | Programmed cell death 1 ligand 1 inhibitor | https://conductscience.org/library/drugs/CHEMBL3707227 | Open Targets |
| CEMIPLIMAB | Phase 3 | 1 | 1 | 1 | PDCD1 | Programmed cell death protein 1 inhibitor | https://conductscience.org/library/drugs/CHEMBL4297723 | Open Targets |
| IPILIMUMAB | Phase 3 | 1 | 1 | 1 | CTLA4 | Cytotoxic T-lymphocyte protein 4 inhibitor | https://conductscience.org/library/drugs/CHEMBL1789844 | Open Targets |
| NIVOLUMAB | Phase 3 | 1 | 1 | 1 | PDCD1 | Programmed cell death protein 1 inhibitor | https://conductscience.org/library/drugs/CHEMBL2108738 | Open Targets |
| CARBOPLATIN | Phase 1/2 | 2 | 2 | 0 | https://conductscience.org/library/drugs/CHEMBL1351 | Open Targets | ||
| DOXORUBICIN | Phase 1/2 | 2 | 2 | 0 | TOP2A | DNA topoisomerase II alpha inhibitor | https://conductscience.org/library/drugs/CHEMBL53463 | Open Targets |
| ADUCANUMAB | Early phase 1 | 1 | 0 | 0 | APP | Amyloid-beta A4 protein binding agent | https://conductscience.org/library/drugs/CHEMBL3039540 | Open Targets |
| AMINOLEVULINIC ACID HYDROCHLORIDE | Early phase 1 | 1 | 0 | 0 | https://conductscience.org/library/drugs/CHEMBL1200582 | Open Targets | ||
| LECANEMAB | Early phase 1 | 1 | 0 | 0 | APP | Amyloid-beta A4 protein inhibitor | https://conductscience.org/library/drugs/CHEMBL3833321 | Open Targets |
Trials95
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07803692 | High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years | Collaborator | Not applicable | Not yet recruiting | Interventional | 10 | 2027-02 | https://conductscience.org/library/trials/NCT07803692 | ClinicalTrials.gov | ||
| NCT07764874 | Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease. | Lead sponsor | Not applicable | Not yet recruiting | Interventional | 120 | 2026-11 | https://conductscience.org/library/trials/NCT07764874 | ClinicalTrials.gov | ||
| NCT06974916 | EMBRACE Tremor BiFUS | Lead sponsor | Not applicable | Recruiting | Interventional | 100 | 2025-04-22 | https://conductscience.org/library/trials/NCT06974916 | ClinicalTrials.gov | ||
| NCT06612788 | Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) | Collaborator | Not applicable | Completed | Interventional | 5 | 2023-09-19 | https://conductscience.org/library/trials/NCT06612788 | ClinicalTrials.gov | ||
| NCT06584383 | A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease | Lead sponsor | Not applicable | Active, not recruiting | Interventional | 67 | 2024-08-01 | https://conductscience.org/library/trials/NCT06584383 | ClinicalTrials.gov | ||
| NCT06367608 | MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD) | Collaborator | Not applicable | Recruiting | Interventional | 10 | 2024-06-10 | https://conductscience.org/library/trials/NCT06367608 | ClinicalTrials.gov | ||
| NCT06292494 | Focused Ultrasound for Drug-resistant Epilepsy | Collaborator | Not applicable | Recruiting | Interventional | 10 | 2024-01-01 | https://conductscience.org/library/trials/NCT06292494 | ClinicalTrials.gov | ||
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | Collaborator | Phase 2 | Withdrawn | Interventional | 0 | 2024-07-30 | PEMBROLIZUMAB | https://conductscience.org/library/trials/NCT05879120 | ClinicalTrials.gov | |
| NCT05630209 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | Lead sponsor | Phase 1/2 | Active, not recruiting | Interventional | 10 | 2023-01-04 | DOXORUBICIN | https://conductscience.org/library/trials/NCT05630209 | ClinicalTrials.gov | |
| NCT05615623 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | Lead sponsor | Phase 1/2 | Active, not recruiting | Interventional | 10 | 2023-01-04 | DOXORUBICIN | https://conductscience.org/library/trials/NCT05615623 | ClinicalTrials.gov |
1 to 10 of 95
See all 95 trialsConditions73
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Essential Tremor | 13 |
| Parkinson Disease | 9 |
| Uterine Fibroids | 8 |
| Bone Metastases | 6 |
| Parkinson's Disease | 6 |
| Brain Tumor | 5 |
| Glioma | 5 |
| Breast Cancer | 4 |
| Glioblastoma | 4 |
| Alzheimer Disease | 3 |
1 to 10 of 73Source ClinicalTrials.gov
See all 73 conditionsPartners18
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| Focused Ultrasound Foundation | Other | 4 | ClinicalTrials.gov | |
| University of Maryland, Baltimore | Other | 3 | ClinicalTrials.gov | |
| Ali Rezai | Other | 1 | ClinicalTrials.gov | |
| Barrow Neurological Institute | Other | 1 | ClinicalTrials.gov | |
| ElMindA Ltd | Industry | 1 | https://conductscience.org/library/companies/elminda-ltd-3a885101 | ClinicalTrials.gov |
| Food and Drug Administration (FDA) | US federal | 1 | ClinicalTrials.gov | |
| Health Canada | Other government | 1 | ClinicalTrials.gov | |
| Imperial College London | Other | 1 | ClinicalTrials.gov | |
| Ivy Brain Tumor Center | Other | 1 | ClinicalTrials.gov | |
| M.D. Anderson Cancer Center | Other | 1 | ClinicalTrials.gov |
1 to 10 of 18
See all 18 partnersData dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/insightec-e0866930
GET https://conductscience.org/api/companies/v1/insightec-e0866930/trials?page=2